Therapeutic Potential Of Recombinant Antibodies To Neutralize Immunogenic Peptides In Celiac Disease

  Address - Spain

  Contact details - 565656565

  Tender notice no. - 76454545

  MT Ref Id - 10337812

  Document Type - Tender Notices

Description - Grant agreement ID: 101030158Start date 1 January 2022End date 31 December 2023Overall budget € 160 932,48ObjectiveCeliac disease affects about 1% of the population worldwide. It is an autoimmune disease triggered by gluten intake in genetically pr edisposed individuals. Celiac disease causes intestinal villi atrophy that results in a deficient absorption of nutrients and other risks. Gluten major sources are wheat, rye, barley and some oats. Currently, the only effective treatment is a permanent gluten free diet (GFD). However, a fully GFD is difficult to achieve. The average daily gluten intake in celiac patients is estimated to be 150-400 mg, when 50 mg are enough to damage the intestine

Mt Ref Id - 10337812

Deadline - Dec 31, 2023